Role of malignant ascites on human mesothelial cells and their gene expression profiles by Isabelle Matte et al.
Matte et al. BMC Cancer 2014, 14:288
http://www.biomedcentral.com/1471-2407/14/288RESEARCH ARTICLE Open AccessRole of malignant ascites on human mesothelial
cells and their gene expression profiles
Isabelle Matte1, Denis Lane1, Dimcho Bachvarov2, Claudine Rancourt1 and Alain Piché1*Abstract
Background: Malignant ascites is often present at diagnostic in women with advanced ovarian cancer (OC) and its
presence is associated with a worse outcome. Human peritoneal mesothelial cells (HPMCs) are key components of
malignant ascites. Although the interplay between HPMCs and OC cells is believed to be critical for tumor
progression, it has not been well characterized. The purpose of this study was to assess the effect of ascites on
HPMCs and clarify the role of HPMCs in OC progression.
Methods: Human OC ascites and benign peritoneal fluids were assessed for their ability to stimulate HPMC
proliferation. Conditioned medium from ascites- and benign fluid-stimulated HPMCs were compared for their ability
to attenuate apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL). We conducted a comparative
analysis of global expression changes in ascites-stimulated HPMCs using Agilent oligonucleotide microarrays.
Results: As compared to benign peritoneal fluids, malignant ascites stimulated the proliferation of HPMCs.
TRAIL-induced apoptosis was attenuated in OC cells exposed to conditioned medium from ascites-stimulated
HPMCs as compared to OC cells exposed to conditioned medium from benign fluid-stimulated HPMCs. A total
of 649 genes were differentially expressed in ascites-stimulated HPMCs. Based on a ratio of more than 1.5-fold
and a P < 0.05, 484 genes were up-regulated and 165 genes were down-regulated in ascites-exposed HPMCs.
Stimulation of HPMCs with OC ascites resulted in differential expression of genes mainly associated with the
regulation of cell growth and proliferation, cell death, cell cycle and cell assembly and organization, compared
to benign peritoneal fluids. Top networks up-regulated by OC ascites included Akt and NF-κB survival pathways
whereas vascular endothelial growth factor (VEGF) pathway was down-regulated.
Conclusions: The results of this study not only provide evidence supporting the importance of the interplay
between cancer cells and HPMCs but also define the role that the tumor environment plays in these
interactions.Background
Epithelial ovarian cancer (EOC) is the leading cause of
death among gynecological cancers. High-grade serous
ovarian carcinomas (HGSOC) are by far the most com-
mon (85-90%) subtype and the majority of patients with
HGSOC presents with ascites and advanced disease with
peritoneal dissemination [1,2]. After initial treatment,
the majority of these patients will relapse and eventually
die. The mean survival of patients that have advanced
disease at presentation is 39 months. This high mortality* Correspondence: alain.piche@usherbrooke.ca
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reproduction in any medium, provided the oris mainly attributed to widespread metastasis throughout
the peritoneal cavity and the emergence of drug resistance
during the course of treatment [3]. OC mortality has not
significantly decreased during the last 30 years for reasons
including poor understanding of the tumor biology and
the interactions with the surrounding environment.
Primary tumor growth induces host responses that are
believed to support and promote tumor progression. OC
mainly spreads by direct extension, through seeding or
exfoliation of tumor cells from ovarian/fallopian tubes
into ascites, in which tumor cells survive and proliferate,
and later implant in the peritoneal cavity. Indeed, the
presence of ascites correlates with intraperitoneal tumor
spread and a worse prognosis. In this context, ascites
that accumulates during OC progression represent atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tumor cells [3,4]. Ascites are complex and heteroge-
neous fluids that contain a variety of cytokines, chemo-
kines and growth factors as well as other soluble factors
such as lysophosphatidic acid (LPA) [5,6]. OC tumorigen-
esis is a complex process and a growing body of evidence
suggests that although genetic events in the tumor cells
themselves are crucial, host and stromal factors in ascites
are also important. For example, OC ascites attenuate
drug-induced apoptosis in tumor cells and thus provide a
protective environment for tumor cells [4]. Soluble factors
in ascites activate survival pathways in tumor cells such as
Akt and ERK1\2 signaling, through engagement of cell
surface receptors such as αvβ5 integrins which attenuate
tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis [7-9]. A number of studies
have also demonstrated that ascites enhance tumor cell
proliferation and migration [10,11]. The presence of LPA
in ascites has been shown to promote tumor cell prolifera-
tion and migration [12]. These data strongly suggest that
malignant ascites plays a significant role in facilitating OC
progression and metastasis.
Human peritoneal mesothelial cells (HPMCs) form the
peritoneal lining and serve as a protective anatomical
barrier. They are among the most abundant cell type in
ascites from patients with OC [13]. Although it is be-
coming evident that paracrine factors secreted in the
resulting tumor environment subsequently modify the
behaviour of tumor cells, a dynamic interaction between
HPMCs found in ascites and the surrounding environ-
ment could alter their behaviour, which in turn, further
affect malignant evolution and contribute to establish a
milieu favouring tumor progression. A number of evi-
dence suggests that morphological and functional changes
of HPMCs occur in the presence of cancer cells due to the
secretion of paracrine factors. For example, HPMCs
increase in size, become more permeable, and undergo an
epithelial to mesenchymal transition (EMT) in the pres-
ence of TGF-β [14-17]. However, precisely how HPMCs
are influenced by ascites is poorly understood.
The aim of this study was to determine the effect of
malignant ascites on HPMC behaviour and the paracrine
effects of ascites-stimulated HPMCs. We also investi-
gated molecular changes that occur in ascites-stimulated
HPMCs. We present evidence that ascites impact on
HPMCs by altering their behaviour and gene expression
profiles.
Methods
Cell culture and clinical samples
The three malignant ascites used in this study (OVC346,
OVC508, OVC509) were obtained at the time of initial
cytoreductive surgery from three ovarian cancer patients
at the Centre hospitalier universitaire de Sherbrooke.Peritoneal fluids were obtained from three patients oper-
ated for conditions other than cancer. This study has
been performed in accordance with the Declaration of
Helsinki and was approved by the «Comité d’éthique de
la recherche en santé chez l’humain du centre hospitalier
universitaire de Sherbrooke».
Fluids were centrifuged at 1000 rpm for 15 min and the
cell-free fractions were stored at -20°C until assayed. All
fluids were supplied by the Banque de tissus et de données
of the Réseau de Recherche en Cancer of the Fonds de la
Recherche du Québec en Santé affiliated to the Canadian
Tumor Repository Network (CTRNet). Histopathological
diagnosis, grade, and stage of ovarian tumor samples were
assigned according to the criteria of the International Fed-
eration of Gynecology and Obstetrics. The three malignant
ascites were from patients with HGSOC (stage III/IV) and
were chosen because they are representative HGSOC asci-
tes with regards to their properties and cytokine profiles
[5,7,8]. The ovarian cancer cell lines CaOV3 and SKOV3
were obtained from American Type Culture Collection,
(Manassas, VA) and maintained in a humidified 5% CO2 in-
cubator at 37°C. Cells were passaged twice weekly. CaOV3
and SKOV3 cells were cultured in DMEM/F12 (Wisent)
supplemented with 10% FBS, 2 mM glutamine and antibi-
otics. HPMCs were isolated from peritoneal lavages of two
women operated for conditions other than cancer. After
centrifugation, the cell pellet is placed on T25 culture
plates. The medium is changed the next day and, in our ex-
perience, adhered cells typically represent HPMCs. The na-
ture of HPMCs was confirmed by immunostaining with
antibodies against calreticulin (Life Technology) and
epithelial marker MOC31 (Oncogen Research Product,
San Diego, CA). HPMCs were grown in DMEM/F12
supplemented with 0.4 μg/ml of hydrocortisone and
10 ng/ml EGF (Sigma, Oakville, Canada), 10% FBS and
antibiotics. The media was changed every 3 days while
the cells were maintained at 37°C in a humidified 5%
CO2 incubator. HPMCs were used between passage 5-8.
Immunofluorescence
Cells were grown on glass slides, fixed in cold methanol
and blocked in PBS/2% BSA at room temperature for
1 h. Anti-calreticulin and anti-MOC31 primary antibodies
were diluted in PBS/BSA and slides were incubated at
room temperature for 1 h. Slides were washed twice in
cold PBS, incubated 1 h at room temperature either with
FITC or Texas-Red conjugated antibodies and visualized
with a Olympus IX70 fluorescence microscope (Olympus,
Hamburg, Germany).
In vitro proliferation assay
HPMCs were seeded in medium either with 10% FBS, with
10% benign fluids or with 10% malignant ascites in six-well
plates and incubated at 37°C. Cells were monitored for up
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some experience, hydroxyurea (30 mM) (Sigma) was added
to inhibit cell proliferation. Two independent experiments
were performed for each assay and representative photo-
graphs were taken. Cell growth was also quantitatively
determined using XTTassay as previously described [7].
RNA preparation and quantitative PCR validation
HPMCs were incubated in medium with either 10%
benign fluids or 10% malignant ascites for 4 h. Cells
were washed with PBS and total RNA was extracted
from HPMCs using TRIzol reagent (Life Technologies)
according to the manufacturer’s protocol and subjected
to reverse transcription (RT) with oligodT from Promega
(Madison, WI) and MMULV reverse transcriptase en-
zyme. The quality and concentration of RNA was deter-
mined by capillary electrophoresis using a Agilent 2100
Bioanalyzer (Agilent Technologies, Mississauga, Ontario,
Canada). The integrity of the cDNA was assessed with
the Taqman gene expression assays (Life Technologies),
done on 18S housekeeping gene. Each sample was normal-
ized to the housekeeping gene levels. For quantitative PCR
validation, total RNA was extracted and cDNA was ob-
tained as described above, The FAST Taqman gene expres-
sion assay was used with 50 ng of cDNA. Conditions were
as follow: initial cycle 50°C, 2 min, 95°C, 10 min. 40 cycles
at 95°C, 15 s and 60°C, 1 min on a StepOnePlusTM Real-
Time PCR system (Life Technologies). Data were analyzed
using the StepOneTM software and comparative ΔΔCt
measure was used to express the results as fold changes.
Gene expression profiling and data analysis
Microarray hybridization was performed using the Whole
Human Genome Oligonucleotide Microarray (Agilent),
containing ~ 44,000 genes, at the Cancer Research Centre,
Hôpital Hôtel-Dieu de Québec. Upon hybridization and
washing, the arrays were scanned using a dual-laser DNA
microarray scanner (Agilent). The data were extracted from
images by the Feature Extraction software 6.1 (Agilent).
The GeneSpring software (Agilent) was used to generate
lists of selected genes for statistical analysis. An intensity-
dependent normalization (Lowess normalization) was ap-
plied to correct for artifacts caused by non-linear rates of
dye incorporation as well as inconsistencies of the relative
fluorescence intensity between dyes. Consecutive lists of
differentially expressed genes were generated considering a
1.5-fold expression as the gene selection criteria. The genes
in the gene lists were classified according to their function
using the Gene Ontology (GO SLIMS) classification sys-
tem. Network analysis of the microarray data was com-
pleted using the Ingenuity Pathway Analysis software
(http://www.Ingenuity.com). The microarray data have
been deposited to the GEO database (http://www.ncbi.
nlm.nih.gov/geo/) with accession number GSE55065.Conditioned media and apoptosis assay
To generate HPMC-conditioned media, HPMCs were
seeded at 80% density in six-well plates and cultured in
media containing either 10% FBS, 10% benign fluids or
10% malignant ascites overnight. Cells were washed
twice and fresh medium without FBS or growth factors
was added. HPMCs were cultured for 8 to 24 h. Medium
conditioned by ascites-stimulated and benign fluids-
stimulated HPMCs were applied at a ratio of 50% v/v to
CaOV3 cells cultured at 70% density in 12-well plates.
CaOV3 cell apoptosis in the presence of TRAIL (25 ng/ml)
(PeproTech Inc, Rocky Hill, NJ) was measured using the Cell
Death Detection ELISA kit (Roche, Laval, Québec, Canada)
according to the manufacturer’s instruction. CaOV3 cells
were pre-treated for 1 h with HPMC-conditioned medium
before the addition of TRAIL overnight. Three independent
sets of experiments were performed for each type of condi-
tioned medium.
Determination of growth factor levels in ascites
LPA levels in benign peritoneal fluids and malignant asci-
tes were determined by ELISA using the Echelon Biosci-
ences kit (Salt Lake City). TGF-β1 levels were determined
using the RayBio® Human Cytokine Antibody Array G
series 1000 from RayBiotech Inc. (Norcross, GA). With
this method, TGF-β1 levels are expressed as relative fluor-
escent units (FU) and can be used to compare levels in dif-
ferent ascites. The signal intensities were quantified using
the ScanArray Express dual-color confocal laser scanner
(Perkin Elmer). Data were collected in Cy3 channel and
stored as paired TiFF images. Spots were identified and
local background substracted using the TIGR_Spotfinder
3.1.1 software. The internal negative controls were used to
determine the cut-off intensity for a positive signal. Inten-
sities up to 750 FU were considered negative.
Results
Characterization of mesothelial cultures from the
peritoneal lining
We established HPMC cultures of peritoneal fluids from
two women with benign conditions. The morphology of
two primary HPMC samples (Meso-7 and Meso-9) cul-
tured in presence of 10% FBS is shown in Figure 1A.
These cells show spindle fibroblastic-like pattern consist-
ent with a mesenchymal phenotype. The primary HPMC
cultures of Meso-7 were further characterized using MOC31
epithelial marker and calretinin mesothelial marker [18]. As
shown in Figure 1B, mesothelial cultures stained positive for
calretinin and negative for MOC31 as expected, confirming
the absence of epithelial cells in HPMCs. In contrast, the
SKOV3 OC cell line stained positive for MOC31 and nega-
tive for calretinin. Furthermore, as previously reported [14],
HPMCs cultured in serum-free medium exhibited a
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Figure 1 Characterization of HPMCs. (A) Phase contrast pictures of HPMCs (Meso-7 and Meso-9) cultured in 10% FBS (x 100 magnification). Bars
200 μm. (B) Immunofluorescence detection of MOC31 and calretinin in human ovarian cancer cells SKOV3 and HPMCs. The cells were fixed with
cold methanol and stained with FITC-conjugated anti-MOC31 and Texas Red-conjugated anti-calretinin (x 1000 magnification). HPMCs stained
positive for calretinin and negative for MOC31 confirming that they were mesothelial cells. Bars 30 μm. (C) HPMCs were cultured either with absence
of FBS, 10% FBS or 10% malignant ascites (OVC508) and representation phase contrast images were taken (x 200 magnification). Bars 100 μm. (D) The
relative expression of TGF-β1 was determined as described in Material & Methods for peritoneal benign fluids (OV370 and OV401) and malignant
ascites (OVC346 and OVC508). The solid line indicates the cut-off intensity (750 FU) for a positive signal. *indicate P < 0.001, T-student test.
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exhibited a more fibroblastic-like pattern.
Because TGF-β1 has been previously associated with
morphologic changes in HMPCs [14], we examined the
levels of TGF-β1 from benign fluids and malignant asci-
tes. Interestingly, the levels of TGF-β1 were significantly
higher (P < 0.001) in malignant ascites compared to
benign fluids (Figure 1D). TGF-β1 levels were below the
threshold for positivity (750 FU) in the two benign peri-
toneal fluids tested.
Malignant ascites stimulate the growth of HPMCs
Malignant ascites constitute a dynamic reservoir of soluble
factors, which individually and in a combined fashion may
affect cell behavior. To assess the putative effect of malig-
nant ascites on the growth of HPMC cultures, we se-
lected two representative ascites (OVC346 and OVC508)obtained from women with newly diagnosed HGSOC. These
malignant ascites have been previously described [5,7,8].
This study included only HGSOC ascites because they
are the most clinically relevant as the majority of
patients presenting with ovarian cancer (80-90%) have
HGSOC. HPMCs were incubated with OVC346 and
OVC508 cell-free ascites fractions and two peritoneal
fluids from women with benign gynecological condi-
tions. Compared to the peritoneal benign fluids, a
growth-enhancing effect was observed with the two
malignant ascites as shown by an increased in overall
cell number after 12 h (Figure 2A). Both OVC346 and
OVC508 malignant ascites had growth-enhancing activity
compared to benign fluids. The growth-enhancing effect
of malignant ascites was completely inhibited by the
addition hydroxyurea, a cell cycle inhibitor. When com-
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Figure 2 Effect of ascites on HPMC proliferation. (A) HPMCs were cultured either with 10% FBS, 10% benign peritoneal fluids or 10%
malignant ascites in the presence or absence of hydroxyurea (HU) for 12 h and phase contrast images were taken (x 200 magnification). Bars
100 μm. (B-C) Phase contrast pictures of Meso-7 and Meso-9 cells cultured either with 10% benign fluid (OV370 or OV401) or 10% malignant ascites
(OVC508 or OVC509). Bars 100 μM. (D) HPMC (meso-7 cells) were seeded and cell growth for up to 96 h was determined by XTT assay. (E) Determination
of LPA levels in benign fluids or malignant ascites. There was no significant difference between levels of LPA in OV401, OVC508 and OVC509 (P > 0.05).
Levels of LPA in OV370 were however significantly higher. *indicate P< 0.01, T-student test.
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ascites (Figure 2B). To ensure that the effect of ascites was
not limited to a single HPMC culture, we also tested theeffect of ascites on Meso-9 mesothelial culture. Malignant
ascites (OVC509) also enhanced the growth of Meso-9,
although these cells grew at a much slower rate than the
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on growth is reproducible in different HPMC culture
(Figure 2C). The cell growth of HPMCs in the pres-
ence of benign fluid (OV401) and malignant ascites
OVC346 was also monitored by XTT assay and dem-
onstrated that OVC346 stimulated cell growth whereas
OV401 did not (Figure 2D). These data suggest that
ascites contain soluble factors that stimulate the prolif-
eration of the two patient-derived HPMC cultures.
LPA is a growth factor-like phospholipid present in the
serum and ascites of patients with OC and promotes tumor
cell proliferation [6]. LPA has been reported to be present at
higher concentration in malignant ascites when compared
to benign fluids [6]. However, we found that LPA levels were
not consistently higher in malignant ascites OVC346 and
OVC508 when compared to benign fluids (Figure 2E).
A more extensive analysis of LPA levels in benign fluids
(n = 17) versus serous OC (n = 20) also failed to show
higher levels of LPA in serous OC (median 1.9 μM±1.1 for
benign fluids versus 3.0 μM±1.9 for serous OC; P > 0.05).
Malignant ascites-stimulated HPMCs secrete soluble factors
that attenuate TRAIL-induced apoptosis
Soluble factors produced by cancer-associated fibroblasts
and bone marrow stromal cells have been shown to con-
fer resistance to TRAIL-induced apoptosis in tumor cells
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1
Figure 3 TRAIL-induced apoptosis in ascites-stimulated HPMCs. (A) Di
HPMCs were culture overnight (shown in yellow), washed TWICE and cultured in
medium (shown in pink) that were collected at either 12 h (B) or different time p
in the presence of TRAIL (25 ng/ml). TRAIL-induced apoptosis was measured in
medium overnight and expressed as fold increased relative to cells that
are expressed as means of triplicates from three independent experimenHPMCs might also secrete soluble factors that could
attenuate TRAIL-induced apoptosis. HPMCs were incu-
bated with benign fluids or malignant ascites overnight.
The cells were then washed twice and conditioned
media (CM) were collected 12 h later. Ovarian cancer
CaOV3 cells were treated with TRAIL in presence of
CM from HPMCs exposed to either benign fluids or ma-
lignant ascites and apoptosis was measured (Figure 3A).
As shown in Figure 3B, TRAIL-induced apoptosis was
decreased in CaOV3 cells exposed to CM from malig-
nant ascites-exposed HPMCs as compared to CM from
benign fluid-exposed HPMCs. These results suggest that
ascites-stimulated HPMCs secrete soluble factors that
attenuate TRAIL-induced apoptosis. To examine the ef-
fect of ascites exposure on the secretion of soluble factors
overtime, HPMCs were stimulated with malignant ascites
or benign fluids overnight. Cells were then washed twice
and CM were collected after 8, 12 and 24 h. Whereas CM
from benign fluid-stimulated HPMCs collected at differ-
ent time did not affect TRAIL-induced apoptosis (OV370,
OV401), CM from ascites-stimulated HPMCs significantly
reduced apoptosis in CaOV3 cells (Figure 3C). The max-
imum protection was observed at 12 h.
Gene expression changes induced by malignant ascites
The expression profiles from HPMC cultures exposed to
peritoneal fluids and OC ascites were compared usingTime (h)
* *
*
























agram of HPMC-priming assays. Ascites-stimulated or benign fluid-stimulated
serum/hormone-free medium for 8 to 24 h to generate HPMC-conditioned
oints (C). HPMC-conditioned medium was then added to CaOV3 tumor cells
CaOV3 cells incubated with the indicated HPMC-conditioned
were exposed to HPMC-conditioned medium but not to TRAIL. Data
ts ± SD. * indicate P < 0.01.
Table 1 Up-regulated genes in HPMCs exposed to malignant ascites versus to benign fluids (Fold change > 2, P < 0.05)
Unigene Symbol Description Functions Fold change
Hs.425633 CKMT1B Creatine kinase mitochondrial 1B Mitochondria 31.80
Hs.282409 CYP2C19 Cytochrome P450, family 2, subfamily C Electron transport 29.10
Hs.560 APOBEC1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 mRNA processing 17.19
Hs.516922 NKX2-2 NK2 transcription factor related locus 2 Transcription 16.20
Hs.553484 ANGPT2 Angiopoietin-2A Angiogenesis 16.16
Hs.145932 MTL5 Metallothionein-like 5 Anti-apoptotic 11.40
Hs.445098 DEPDC1 DEP domain containing 1 Intracellular signaling 7.06
Hs.149924 LILRB1 Leucocyte immunoglobulin-like receptor, subfamily B Immune response 6.31
Hs.471494 EIF2C4 mRNA for KIAA1567 Protein synthesis 6.06
Hs.272215 KLF15 Kruppel-like factor 15 Transcription 5.74
Hs.285829 DLEU7 Deleted in lymphocytic leukemia 7 Intracellular signaling 5.23
Hs.6702 KCNB2 Potassium voltage-gated chanel Cation transport 5.08
Hs.351403 DZIP1L DAZ interacting protein 1-like Ion binding 4.60
Hs.479853 EPHA5 EPH receptor A5 Intracellular signaling 4.54
Hs.122583 UTG2A3 UDP glucuronosyltransferase 2 family Metabolism 4.23
Hs.446021 SLC37A3 Solute carrier family 37 Transport 4.02
Hs.270833 AREG Amphiregulin Cell proliferation 3.52
Hs.467793 FLJ40869 Hypothetical protein FLJ40869 DNA repair 3.31
Hs.441975 BIRC4BP XIAP-associated factor 1 Ion binding 3.26
Hs.531941 MYB myeloblastosis viral oncogene homolog Transcription 2.83
Hs.585869 ZNF224 Zinc finger protein 224 Transcription 2.57
Hs.188518 MT1K Metallothionein 1 K Ion binding 2.54
Hs.190043 MOSPD2 Motile sperm domain containing 2 Membrane protein 2.52
Hs.270543 GNB4 Guanine nucleotide binding protein, beta polypeptide 4 Intracellular signaling 2.44
Hs.190622 DDX58 DEAD box polypeptide 58 DNA binding 2.37
Hs.658169 SFRP4 Secreted frizzled-related protein 4 Intracellular signaling 2.37
Hs.13852 DNAJB4 Hsp40 homolog, subfamily B, member 4 Protein folding 2.36
Hs.189920 PB1 Polybromo 1 Transcription 2.35
Hs.513044 CSPG4 Chondroitin sulfate proteoglycan 4 Cell motility 2.32
Hs.520506 FBXO5 F-box protein 5 Protein degradation 2.28
Hs.83634 HCFC1 Host cell factor C1 Cell proliferation 2.25
Hs.14794 ZFP28 Zinc finger protein 28 homolog Transcription 2.19
Hs.10319 UGT2B7 UDP glucuronosyltransferase 2 family Metabolism 2.17
Hs.503093 ZFP36L2 Zinc finger protein 36, C3H type-like 2 Cell proliferation 2.14
Hs.110915 IL22RA1 Interleukin 22 receptor, alpha 1 Immune response 2.13
Hs.442344 IRS2 Insulin receptor substrate 2 Cell proliferation 2.11
Hs.479670 TEC Tec protein tyrosine kinase Intracellular signaling 2.10
Hs.167700 SMAD5 SMAD, family member 5 Transcription 2.10
Hs.541894 ANKRD36 Ankirin repeat domain 36 Catalytic activity 2.09
Hs.655199 MT1A Metallothionein 1A Ion binding 2.09
Hs.407190 FKBP5 FK506 binding protein 5 Protein folding 2.06
Hs.744289 ZNF549 Zinc finger protein 549 Ion binding 2.06
Hs.431550 MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 Intracellular signaling 2.04
Hs.433702 EIF5 Eukaryotic translation initiation factor 5 Translation 2.04
Hs.167584 SLC2A2 Solute carrier family 2 Transport 2.03
Hs.405144 SFRS3 Splicing factor, arginine/serine-rich 3 RNA binding 2.02
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Table 2 Down-regulated genes in HPMCs exposed to malignant ascites versus to benign fluids (Fold change > 2,
P < 0.05)
Unigene Symbol Description Functions Fold change
Hs.602085 PHLDA1 Pleckstrin homology-like domain, member 1 Nuclear protein -3.40
Hs.624 IL-8 Interleukin 8 Angiogenesis -3.38
Hs.98367 SOX17 SRY-box 17 Transcription -3.33
Hs.345139 GEM GTP binding protein overexpressed in skeletal muscle Intracellular signaling -2.58
Hs.73853 BMP2 Bone morphogenetic protein 2 Cell proliferation -2.58
Hs.251526 CCL7 Chemokine ligand 7 Inflammatory response -2.54
Hs.591159 PTHLH Parathyroide hormone-like hormone Ion binding -2.44
Hs.643357 ADAMTS1 A disintegrin and metallopeptidase with thrombospondin type 1 Cell proliferation -2.34
Hs.517310 RIPK4 Receptor-interacting serine-threonine kinase 4 Intracellular signaling -2.32
Hs.616962 GDF15 Growth differentiation factor 15 Intracellular signaling -2.31
Hs.279522 NR4A3 Nuclear receptor subfamily 4, group A, member 3 Transcription -2.30
Hs.25829 RASD1 RAS, dexamethasone-induced 1 Intracellular signaling -2.27
Hs.516826 TRIB3 Tribbles homolog 3 Transcription -2.22
Hs.406714 KRTAP2-4 Keratin associated protein 2-4 Cell structure -2.20
Hs.505146 CLDN14 Claudin 14 Cell-cell adhesion -2.20
Hs.799 HBEGF Heparin-binding EFG-like growth factor Growth factor -2.18
Hs.525572 BDKRB1 Bradykinin receptor B1 Inflammatory response -2.18
Hs.191215 PSCD1 Pleckstrin homology, Sec7 and coiled-coil domains Transport -2.07
Hs.76095 IER3 Immediate early response 3 Apoptosis -2.04
Hs.18676 SPRY2 Sprouty homolog 2 Cell-cell signaling -2.03
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(Agilent), containing ~ 44,000 genes. Microarrays were
performed on HPMCs exposed to 3 malignant ascites
from women with advanced (stage III/IV) serous OC
and two benign peritoneal fluids. First, we generated
lists of significantly up-regulated and down-regulatedA
Up-regulated upon malignant ascites treatment 
Figure 4 Functional analysis for the dataset of differentially expressed g
meet a P value cutoff of 0.05 are displayed. The orange line represents the
(B) genes down-regulated.genes that were differentially expressed between OC
ascites (OVC346, OVC508 and OVC509) and control
OV370 peritoneal fluid. Then, the set of genes that
were commonly expressed between control peritoneal
fluids (OV370 and OV401) were subtracted from the
first list of genes to generate a dataset of differentiallyB
Down-regulated upon malignant ascites treatment 
enes (≥ 1.5-fold) in ascites-stimulated HPMC cells. Top functions that
cutoff value for significance. (A) Genes that were up-regulated and
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http://www.biomedcentral.com/1471-2407/14/288expressed genes between malignant ascites and benign
peritoneal fluids. A subset of 649 genes was thus
selected by filtering on confidence at P value = 0.05,
followed by filtering on expression levels (≥ 1.5 fold).
We found 484 genes to be commonly up-regulated and
185 genes to be down-regulated in HPMCs exposed to
malignant ascites. Top molecules that were up-regulated
are shown in Table 1 and those down-regulated in Table 2.
Pathway and network analysis based on the 649 genes list
were generated through the use of Ingenuity Pathways
Analysis (IPA). IPA showed that the top two pathways
up-regulated in this gene list were functionally associated
with the regulation of cell cycle and apoptosis (Figure 4A)
which is consistent with data from Figures 2 and 3. Genes
implicated in cell death and cell growth and proliferation
(mostly negative regulators) were among the top pathways
down-regulated (Figure 4B) (Table 3). Networks linked to
cancer, inflammatory response, cell movement, cell assem-
bly and organization, cell-to-cell signaling, DNA replica-
tion, and repair and recombination were both induced or
suppressed. The analysis recognized several important
nodes linked with numerous partners, including nuclear
factor-κB (NF-κB), Akt, heat shock protein 90 (Hsp90),
hepatocyte nuclear factor 4α (HNF-4α), KRAS, SMAD1,
RNA helicase p68 (DDX5B, p68), c-KIT ligand (KITLG),
vascular endothelial growth factor (VEGF), interleukin-8Table 3 Cell death biological function category showing a
significant fold change in genes belonging to HPMCs
exposed to malignant ascites compared to benign fluids
(Fold change > 2, P < 0.05)
Symbol Description Fold change
BDKRB1 Bradykinin receptor B1 -2.18
IL-8 Interleukin 8 -3.38
SOX17 SRY-box 17 -3.33
BMP2 Bone morphogenetic protein 2 -2.58
NR4A3 Nuclear receptor subfamily 4, group A,
member 3
-2.30
RASD1 RAS, dexamethasone-induced 1 -2.27
PHLDA1 Pleckstrin homology-like domain, member 1 -3.40
TRIB3 Tribbles homolog 3 -2.22
HBEGF Heparin-binding EFG-like growth factor -2.20
SPRY2 Sprouty homolog 2 -2.03
AREG Amphiregulin 3.52
DDX58 DEAD box polypeptide 58 2.37
DEPDC1 DEP domain containing 1 7.06
IRS2 Insulin receptor substrate 2 2.11
SMAD5 SMAD, family member 5 2.10
MT1A Metallothionein 1A 2.10
MAP4K4 Mitogen-activated protein kinase kinase
kinase kinase 4
2.04(IL-8), follicle stimulating hormone (FSH), colony stimu-
lating factor 2 (CSF2), cyclin-dependent kinase inhibitor
1A (CDKN1A, p21, Clip1), bone morphogenetic protein 2
(BMP2) (Figure 5A and B). While some of the up-regulated
gene nodes and related pathways were associated with posi-
tive feedbacks on the cell cycle (NF-κB, KRAS, KITLG,
MAP4K4, HCFC1), some down-regulated genes were nega-
tive regulators of the cell cycle (CDKN1A/2B, DUSP6/10).
Validation of microarray findings with quantitative RT-PCR
To validate the results of the microarray analysis, we
used quantitative real-time PCR to quantify the expres-
sion of selected genes including PTHLH, INHBA, PHLDA1,
IRS2 and KTR-18 in ascites-stimulated HPMCs compared
to benign fluid (OVC370, OVC401)-stimulated HPMCs.
qRT-PCR analysis confirmed our microarray findings for
PTHLH, INHBA and PHLDA1 genes which were down-
regulated, and for IRS2 and KTR-18 which were up-
regulated (Figure 6A). qRT-PCR analysis was also performed
with a third peritoneal fluid OV1081 along with OV370 to
validate the differential expression of IL-8 and BMP2 in
malignant ascites (Figure 6B). The expression of IL-8 and
BMP2 were down-regulated in HPMCs stimulated with
malignant ascites as compared to both OV1081 and OV370
benign fluids.
Discussion
A crucial step in OC progression is the ability of tumor
cells to shed from the primary tumor site and proliferate
and survive in ascites. In this context, ascites must pro-
vide a milieu that support tumor cell growth. OC ascites
are rich, heterogeneous and complex fluids that harbor a
wide variety of soluble factors that are part of an auto-
crine and paracrine network in tumor cells. In line with
these observations, the presence of ascites correlates
with peritoneal spread of OC tumors [22] and signifi-
cantly decreases the 5-year survival rate for women with
advanced OC [23]. Malignant ascites offer OC cells a
network of proliferative and survival factors; thus OC
cells floating in ascites receive signals that alter gene
expression which confer a survival advantage. Indeed, it
was recently demonstrated that ascites promote the acti-
vation of survival pathways in tumor cells, which contrib-
ute to attenuate drug-induced apoptosis [7-9]. Changes in
tumor cell behavior are mediated by the activation of vari-
ous signaling pathways such as PI3K/Akt and MAPK/ERK
pathways in these cells [8,9]. HPMCs present in ascites are
theoretically exposed to those same factors and conse-
quently receive similar signals. To better understand the
role of HPMCs in OC progression and how ascites signals
may alter their behavior, we characterized the effects of
malignant ascites on HPMC morphology and prolifera-
tion, and correlated these effects with molecular alter-
ations in gene expression occurring in HPMCs after
Figure 5 Network analysis of dynamic gene expression in ascites-stimulated HPMCs based on the common up-regulated (A) or down-
regulated (B) (≥ 1.5-fold) gene expression list obtained following stimulation with all three malignant ascites. The top-scoring networks
were merged and displayed graphically as node (gene/gene product) and edges (the biological relationships between the nodes). Nodes are
displayed using various shapes that represent the functional class of the gene product (square, cytokine; vertical oval, transmembrane receptor;
rectangle, nuclear receptor; diamond, enzyme; rhomboid, transporter; hexagon, translation factor; horizontal oval, transcription factor; circle, other).
Edges are displayed with various labels that described the nature of relationship between the nodes:— binding only;→ acts on. The length of an
edge reflects the evidence supporting that node-to-node relationship, in that edges supported by article from literature are shorter. Dotted edges
represent indirect interaction.
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two patient-derived HPMC cultures that were derived
from peritoneal fluids and exposed these cells to either
malignant ascites or benign peritoneal fluids. We analyzed
functionally related genes that were commonly differen-
tially expressed following exposure of HPMCs to all ma-
lignant ascites compared to benign peritoneal fluids.
The current study demonstrates that OC ascites con-
sistently induce a switch of morphology in HPMCs from
an epithelial to a fibroblastic pattern, a finding that has
been reported by other groups when HPMCs were incu-
bated with TGF-β1 [14,15]. In contrast, benign fluids
failed to induce such a switch. Interestingly, levels of
TGF-β1 were below the threshold of positivity in benign
fluids whereas TGF-β1 was detectable in malignant ascites,
although levels were low (~ 1400 FU). TGF-β1 is consid-
ered a critical regulator of epithelial-to-mesenchymal tran-
sition (EMT). The essential features of EMT include the
downregulation of epithelial cell markers (e.g. E-cadherin,
claudins) and the upregulated expression of fibroblastic
markers (e.g. vimentin, N-cadherin). TGF-β1-induced
EMT is mediated by Smad-dependent and –independent
signaling [24]. Whether the low level of TGF-β1 found inmalignant ascites is responsible for the morphologic
changes that were observed in HPMCs is unclear. Smad1
and Smad5 genes were up-regulated by malignant ascites
which is consistent with the involvement of TGF-β1. Sig-
naling pathways involved in EMT such as PI3K/Akt and
Ras/MAPK were also up-regulated by malignant ascites
(Figure 5A). All these findings are consistent with an im-
portant role for TGF-β1. However, growth factors other
than TGF-β1, such as hepatocyte growth factor (HGF),
fibroblast growth factor (FGF) or epidermal growth factor
(EGF), which are found in malignant ascites [5], may also
activate these signaling pathways and induce EMT [24]. In
the current study, we observed that the three OC ascites
tested stimulated the proliferation of HPMCs. In contrast,
the two peritoneal fluids did not stimulate proliferation.
This suggests that the malignant ascites tested contain
growth-promoting activity. In line with this observation,
malignant ascites were also found to stimulate the prolif-
eration of OC cells in vitro [10]. Malignant ascites contain
several growth factors that could potentially stimulate the
proliferation of mesothelial cells [5]. Among these factors,
LPA is of particular interest. In the present study, we
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Figure 6 Correlation between gene expression data and quantitative PCR. (A) Levels of mRNA expression in ascites-stimlated HPMCs
expressed as fold changes relative to benign fluiids OVC370- or OVC401-stimulated HPMCs. (B) Relative expression of IL-8 and BMP-2 mRNA in
ascites-stimulated HPMCs compared to either benign fluid OV1081- or OVC370-stimulated HPMCs. * indicate P < 0.03.
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http://www.biomedcentral.com/1471-2407/14/288and in benign fluids (Figure 2E). It has been previously
reported that LPA is present at 20-80 μM concentrations
in the ascites of OC patients [25-27]. LPA is a factor in
ascites from OC patients that promote the proliferation as
well as the migration of OC cells [28-30]. Serous OC LPA
levels were lower in this study (median 3.0 μM) compared
to previous studies. Most importantly however, the levels
of LPA were not significantly different in serous OC com-
pared to benign fluids. These observations suggest that, in
the two malignant ascites tested, LPA may not be a critical
factor for ascites-mediated proliferation of the two sam-
ples of HPMCs.
Consistent with the findings that malignant ascites
stimulate HPMC proliferation in vitro, we found that cell
cycle- and cell growth-related genes were up- and down-regulated by malignant ascites. In total, the expression of
85 genes involved in cell proliferation was altered by
malignant ascites. In particular, several cyclin-dependent
kinase (Cdk) inhibitors (p21, p15) and dual specificity
phosphatases (DUSP6, DUSP10) were down-regulated.
Upon stimulation by growth factors, downstream targets
such as cyclin D1 are activated by the ERK pathway,
which is activated by LPA [30], resulting in progression
from G1 to S. Cdks inhibitors such as p21 and p15 can
block G1 progression. Dusp6 and Dusp10 acts as nega-
tive feedback regulators of ERK signalling [24,31]. Con-
versely, genes such as receptor tyrosine kinase KIT, its
ligand stem cell factor (SCF) and KRAS, which induce
ERK phosphorylation and promote cell proliferation
[32], were upregulated by ascites.
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duce the secretion of factors by HPMCs (at least in the
meso-7 samples) that attenuate TRAIL-induced apop-
tosis in tumor cells. This observation implies that ascites
activate HPMCs through paracrine interactions and acti-
vated HPMCs secrete factors that promote the survival of
tumor cells. Indeed, many genes differentially expressed in
HPMCs stimulated by malignant ascites are closely related
to the regulation of apoptosis. The apoptosis-related genes
include a total of 47 genes that were down-regulated and
58 that were up-regulated (Figure 4). Interestingly, stem
cell factor (SCF) and its receptor (c-kit) were among the
genes that were up-regulated. Myb transcription factor,
which serves as a regulator of c-kit expression, was
up-regulated by ascites in HPMCs. SCF/c-kit pathway has
been implicated in a variety of processes including cell
survival [33]. SCF signals via c-kit through PI3K/Akt and
Ras/MAPK pathways, two well-establish survival pathways
[33]. Ahmed et al. showed that ascites activate Ras/MAPK
signaling in OC cells [34]. Our group also demonstrated
that OC ascites stimulate MAPK/ERK1/2 pathway leading
to the regulation of Mcl-1 antiapoptotic protein in OC
cells [9].
Conclusions
In summary, this study provides evidence that activation
of HPMCs is mediated by paracrine interactions with
soluble factors in malignant ascites. These factors stimulate
a phenotypic shift from an epithelial to a fibroblastic
morphology in HPMCs. Ascites-stimulated HPMCs are
proliferative and secrete soluble factors that promote tumor
cell survival. Although the nature of these factors remains
to be determined, they likely promote a survival advantage
for tumor cells. Paracrine factors in ascites activate intracel-
lular signaling network such as Akt and NF-κB in HPMCs
whichmediate, in turn, the up-regulation of HPMC-secreted
factors that impact OC progression. One limitation of this
study is that data were derived from a small number of
samples, thus conclusions should be viewed appropriately.
Validation in a larger set of patients will be beneficial.
Future studies assessing the nature of paracrine and autocrine
stimulating signals will help to better define the interplay
between HPMCs and tumor cells that is important for OC
progression.
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